Novo, HBM lead CHF 100m round for Numab


Novo Ventures and HBM Partners have led a CHF 100m series-C funding round for Switzerland-based Numab Therapeutics, a multi-specific antibodies developer.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *